Alecensa (alectinib) for Treatment of ALK-positive Non-small Cell Lung Cancer
Alecensa (alectinib) is a kinase inhibitor intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Pharmaceuticals